• Company
• First-ever RET inhibitor 'Retevmo' attempts reimbursement
• by Eo, Yun-Ho Mar 31, 2022 05:58am

• Policy
• Reimbursement priorities in ultra-high-priced one-shot Txs
• by Lee, Tak-Sun Mar 31, 2022 05:57am

• Company
• Kidney care is also important for diabetic patients
• by Eo, Yun-Ho Mar 30, 2022 06:09am

• Opinion
• [Reporter’s View] Regrets in GOV's COVID-19 responses
• by Mar 30, 2022 06:09am

• Company
• Dupixent shows marked effect in Korean severe asthma patient
• by Mar 30, 2022 06:09am

• Policy
• Multidrug-resistant ‘Zavicefta’ applies for approval
• by Lee, Hye-Kyung Mar 29, 2022 05:54am

• Policy
• Will the migraine tx Reyvow step on the same track
• by Lee, Tak-Sun Mar 29, 2022 05:54am

• Company
• Daewoong’s ‘Fexclu’ speeds up overseas market penetration
• by Kim, Jin-Gu Mar 29, 2022 05:54am

• Product
• Only Paxlovid's prescription continues instead of Lagevrio
• by Jung, Heung-Jun Mar 29, 2022 05:54am

• Policy
• BMS acute myeloid leukemia tx Onureg was approved
• by Lee, Hye-Kyung Mar 29, 2022 05:54am